Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $2,138.15 today based on a price of $325.64 for ALNY at the time of writing.

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a ...

Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech ...

Present Market Standing of Alnylam Pharmaceuticals With a volume of 918,360, the price of ALNY is up 1.19% at $257.76. RSI indicators hint that the underlying stock may be overbought. Next ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $339.39, a high estimate of $500.00, and a low estimate of $268.00.

Alnylam Pharmaceuticals has seen its stock rise by 17% this year. The stock now trades at over 33x projected 2020 revenues, despite the fact that the company is likely to post another loss this year.

Oct 9 (Reuters) - Alnylam Pharmaceuticals , opens new tab said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug ...